Furthermore, the same group was able to show that the MET oncogene is involved in miR-221/222 activation and that miR-130a, by targeting MET, reduces TRAIL resistance in NSCLC cells through down-regulation of miR-221/222 [95]. Here, MET is linked to non-small cell lung carcinoma.